Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Objectives: Bipolar patients frequently relapse within 12 months of their previous mood episode, even in the context of adequate treatment, suggesting that better continuation and maintenance treatments are needed. Based on recent research of the pathophysiology of bipolar disorder, we review the evidence for mitochondrial dysregulation and selected mitochondrial modulators (MM) as potential treatments. Methods: We reviewed the literature about mitochondrial dysfunction and potential MMs worthy of study that could improve the course of bipolar disorder, reduce subsyndromal symptoms, and prevent subsequent mood episodes. Results: MM treatment targets mitochondrial dysfunction, oxidative stress, altered brain energy metabolism and the dysregulation of multiple mitochondrial genes in patients with bipolar disorder. Several tolerable and readily available candidates include N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q 10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin. The specific metabolic pathways by which these MMs may improve the symptoms of bipolar disorder are discussed and combinations of selected MMs could be of interest as well. Conclusions: Convergent data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder. Clinical trials of individual MMs as well as combinations are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
Wellcome Trust Case Control Consortium, Ferreira, M. A. R., O'Donovan, M. C., Meng, Y. A., Jones, I. R., Ruderfer, D. M., Jones, L., Fan, J., Kirov, G., Perlis, R. H., et al. (2008) · Nature Genetics · doi:10.1038/ng.209 · Cited by 1,237 · cited 1×
“Mitochondrial variation is also of particular interest in light of the recent association between calcium channel variation and bipolar disorder (Ferreira et al., 2008; Sklar et al., 2008).”
BackgroundSelf-citationOxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 4×
“While glycolysis is a readily available source of energy, it only manufactures 2 ATP per glucose molecule in contrast to the 36 ATP produced through oxidation phosphorylation (Ng et al., 2008).”
BackgroundInfluentialEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“Patients with early, untreated Parkinson’s disease showed a slower decline in functioning when CoQ10 was given at a dose of 1200 mg/day (Shults et al., 2002), a dose that has been Australian & New Zealand Journal of Psychiatry, 47(1) found to have a good safety profile (Hidaka et al., 2008).”
BackgroundN-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency
Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.005 · Cited by 721 · cited 1×
“NAC, by supplying cysteine, increases synthesis of the free radical scavenger glutathione (GSH) which, in turn, reduces oxidative stress (Atkuri et al., 2007).”
BackgroundPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
CNS energy metabolism as related to function
Ames, A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00038-2 · Cited by 663
Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts
Nicholls, D. G., & Ward, M. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01534-9 · Cited by 563
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Ziegler, D., Hanefeld, M., Ruhnau, K. J., Mei\ner, H. P., Lobisch, M., Sch�tte, K., Gries, F. A., & The ALADIN Study Group (1995) · Diabetologia · doi:10.1007/bf00400603 · Cited by 525 · cited 1×
“…functioning and impaired energy utilization, including type II diabetes (Jacob et al., 1999) and diabetic polyneuropathy (Ametov et al., 2003; Hahm et al., 2004; Negrisanu et al., 1999; Reljanovic et al., 1999; Ruhnau et al., 1999; Tankova et al., 2004; Ziegler et al., 1995, 1999, 2006).”
BackgroundBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
The selfish brain: Competition for energy resources
Peters, A., Schweiger, U., Pellerin, L., Hubold, C., Oltmanns, K. M., Conrad, M., Schultes, B., Born, J., & Fehm, H. L. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.03.002 · Cited by 489
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 2×
“…(Tarnopolsky et al., 2004; Walter et al., 2000) and neurodegenerative disorders such as Parkinson’s disease (Bender et al., 2006; NINDS NET-PD Investigators, 2006), Huntington’s disease (Tabrizi et al., 2005; Verbessem et al., 2003) and ALS (Groeneveld et al., 2003; Rosenfeld et al., 2008)…”
BackgroundDirect antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 3×
“…supplementation was found to have indirect antioxidant properties in an animal model of traumatic brain injury that were associated with reduced apoptosis, prevention of opening of the MPTP, and better maintenance of the mitochondrial membrane potential (Lawler et al., 2002; Sullivan et al., 2000).”
BackgroundMitochondrial dysfunction and pathology in bipolar disorder and schizophrenia
Clay, H. B., Daws, S., & Konradi, C. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.08.007 · Cited by 399 · cited 6×
“We postulate that MMs are candidates for novel treatments based on the latest studies of mitochondrial abnormalities (Clay et al., 2011) and alterations of brain energy metabolism (Frey et al.”
BackgroundInfluentialShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326 · cited 1×
“Impaired activity of complex I, II and III was observed in platelet mitochondria of patients with early, untreated Parkinson’s disease (Shults et al., 1997).”
BackgroundPapakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09081198 · Cited by 297
Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293
Jacob, S., Ruus, P., Hermann, R., Tritschler, H. J., Maerker, E., Renn, W., Augustin, H. J., Dietze, G. J., & Rett, K. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00089-1 · Cited by 280 · cited 1×
“…a number of diseases thought to be associated with abnormal mitochondrial functioning and impaired energy utilization, including type II diabetes (Jacob et al., 1999) and diabetic polyneuropathy (Ametov et al., 2003; Hahm et al., 2004; Negrisanu et al., 1999; Reljanovic et al., 1999; Ruhnau et…”
BackgroundBeneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Judd, L. L., Schettler, P. J., Akiskal, H. S., Coryell, W., Leon, A. C., Maser, J. D., & Solomon, D. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.386 · Cited by 251
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223 · cited 2×
“A more recent study investigating a higher dosage of CoQ10 in conjunction with vitamin E suggested that CoQ10 is safe and tolerated at doses up to 3000 mg/day for 2 weeks, but should not exceed 2400 mg/day since any dosage beyond this amount does not increase plasma levels of alphatocopherol (Shults et al., 2004).”
BackgroundKato, T., Takahashi, S., Shioiri, T., Murashita, J., Hamakawa, H., & Inubushi, T. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90116-3 · Cited by 223
Increase of total creatine in human brain after oral supplementation of creatine-monohydrate
Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221
Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy
Tarnopolsky, M. A., Mahoney, D. J., Vajsar, J., Rodriguez, C., Doherty, T. J., Roy, B. D., & Biggar, D. (2004) · Neurology · doi:10.1212/01.wnl.0000125178.18862.9d · Cited by 216 · cited 2×
“Several clinical trials with CM in the treatment of mitochondrial cytopathies (Tarnopolsky et al., 1997), neuromuscular disorders (Tarnopolsky et al., 2004; Walter et al., 2000) and neurodegenerative disorders such as Parkinson’s disease (Bender et al., 2006; NINDS NET-PD Investigators, 2006),…”
BackgroundMethodStorch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205 · cited 1×
“Other evidence found that while CoQ10 supplementation increased plasma levels of CoQ10 in patients with Parkinson’s disease, it had no effect on Parkinsonian symptoms after a 3-month period (Storch et al., 2007).”
BackgroundThe expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia
Benes, F. M., Matzilevich, D., Burke, R. E., & Walsh, J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001758 · Cited by 183 · cited 4×
“Mitochondrial gene expression in bipolar disorder Multiple mitochondrial genes have been found to be upregulated or downregulated in bipolar disorder compared to normal controls (Benes et al., 2006; Munakata et al., 2004; Naydenov et al., 2007; Sun et al., 2006; Wang, 2007).”
BackgroundResultInfluentialThe mitochondrial permeability transition
Bernardi, P., Colonna, R., Costantini, P., Eriksson, O., Fontaine, E., Ichas, F., Massari, S., Nicolli, A., Petronilli, V., & Scorrano, L. (1998) · BioFactors · doi:10.1002/biof.5520080315 · Cited by 183
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Cui, J., Shao, L., Young, L. T., & Wang, J.-F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.010 · Cited by 160 · cited 4×
“As reviewed below, mitochondrial dysfunction in bipolar disorder is associated with decreased ATP production, indicated by decreased brain energy metabolism and a shift from oxidative phosphorylation to anaerobic glycolysis (Cui et al., 2007; Frey et al., 2007a; Naydenov et al., 2007; Stork and Renshaw, 2005) (as show…”
BackgroundResultInfluentialSohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143 · cited 2×
“While the total level of plasma CoQ10 was reduced in subjects with Parkinson’s disease, Australian & New Zealand Journal of Psychiatry, 47(1) Australian & New Zealand Journal of Psychiatry, 47(1) the percentage of oxidized plasma CoQ10 (ubiquinone-10) was increased (Sohmiya et al., 2004).”
BackgroundLyoo, I. K., Kong, S. W., Sung, S. M., Hirashima, F., Parow, A., Hennen, J., Cohen, B. M., & Renshaw, P. F. (2003) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(03)00046-5 · Cited by 140
Creatine monohydrate in resistant depression: A preliminary study
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00532.x · Cited by 118
Torrioli, M. G., Vernacotola, S., Peruzzi, L., Tabolacci, E., Mila, M., Militerni, R., Musumeci, S., Ramos, F. J., Frontera, M., Sorge, G., et al. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32268 · Cited by 100 · cited 1×
“…2002; Tempesta et al., 1987; Villardita et al., 1983), dysthymia (Zanardi and Smeraldi, 2006), hyperactivity associated with fragile X syndrome (Torrioli et al., 1999, 2008), ADHD, inattentive type (Arnold et al., 2007), degenerative cerebellar ataxia (Sorbi et al., 2000), minimal hepatic…”
BackgroundQ10 therapy in patients with idiopathic Parkinson's disease
Strijks, E., Kremer, H. P. H., & Horstink, M. W. I. M. (1997) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(97)00008-3 · Cited by 45 · cited 1×
“Similarly, in an open label trial of 200 mg of daily CoQ10 supplementation, idiopathic parkinsonian patients demonstrated no significant clinical effect in a 3-month period (Strijks et al., 1997).”
BackgroundAcetyl-L-carnitine and α-lipoic acid: possible neurotherapeutic agents for mood disorders?
Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., & McIntyre, R. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.827 · Cited by 23
Cited by
A model of the mitochondrial basis of bipolar disorder
Morris, G., Walder, K., McGee, S. L., Dean, O. M., Tye, S. J., Maes, M., & Berk, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.014 · Cited by 162
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions
Nemeroff, C. B., Weinberger, D., Rutter, M., MacMillan, H. L., Bryant, R. A., Wessely, S., Stein, D. J., Pariante, C. M., Seemüller, F., Berk, M., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-202 · Cited by 128
“This is concordant with new research on the primacy of energy clinically, reflecting new data on the role of mitochondrial energy generation in the disorder, as well as the poor specificity of ‘irritability’ [43].”
ResultCognitive Dysfunction in Depression – Pathophysiology and Novel Targets
Carvalho, A., Miskowiak, K., Hyphantis, T., Kohler, C., Alves, G., Bortolato, B., G. Sales, P., Machado-Vieira, R., Berk, M., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203627 · Cited by 107
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96
“disorder and remediation with CoQ10 [48].”
Metadata
- Authors
- Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R., & Iosifescu, D. V.
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2012-06-18
- Volume
- 47
- Issue
- 1
- Pages
- 26-42
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2117463469
- Cited by
- 76
- References
- 37
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.